Kidney drug approval gives Shire some breathing space THE 64,000 dollar - correction, make that 500 million dollar -uestion hanging over Shire Pharmaceuticals is whether the 5 per cent jump in the companys shares yesterday reflects relief that US regulators have finally approved its drug for 